Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2020

View Archived Issues

Nuvation conducts phase I/II study of NUV-422 in recurrent or refractory high-grade gliomas

Celyad begins phase I trial of CYAD-211 for relapsed or refractory multiple myeloma

Jacobio initiates first-in-human study of JAB-8263 in advanced solid tumors

Natural killer cells kill aging cognition

Enrollment open in phase Ib/II study of KRT-232 with acalabrutinib in DLBCL and CLL

ION-251 enters first-in-human trial for relapsed or refractory multiple myeloma

Positive data presented from global MOMENTUM trial of SRP-5051

Topline data from phase III DARE-BVFREE study of DARE-BV1 in women with bacterial vaginosis

Relmada initiates phase III program for REL-1017 as adjunctive therapy in MDD

FDA issues complete response letter for Furoscix

QLB Biotherapeutics describes bispecific anti-CD3 and CD20 antibodies

ACSS2 inhibitors discovered at Metabomed

UCB patents antimalarials

New GBA2 inhibitors disclosed by Alectos Therapeutics

Teligene identifies new protein kinase inhibitors

"Transomics" show altered glucose metabolism in obesity

Lyra Therapeutics presents positive data from phase II LANTERN study of LYR-210

Phase I/II data support further study of CAR T-cell therapy MB-CART2019.1 in B-cell NHL

FDA allows IND for phase I/II trial of Artiva's NK cell therapy AB-101 for NHL

FDA clears IND for first-in-human study of KB-0742 for MYC-amplified tumors

Vicore reports topline data on use of C-21 for COVID-19

Axsome reports phase II data on AXS-05 in patients with MDD with suicidal ideation

QRA-244 could counteract disease progression due to hyperexcitability in patients with ALS

Ysopia begins phase I trial of Xla-1 for obesity and metabolic disorders

FDA accepts IND for phase Ib study of CERC-007 for relapsed or refractory multiple myeloma